

Table S4. Baseline characteristics, response pattern and their correlations with progression pattern* (dichotomous outcome) (bivariate analysis, n=166)

Baseline Characteristics	General progression pattern [~]	
	OR (95% CI)	P value
Age[§]	0.977 (0.955 to 0.999)	.04
Sex[#]	0.722 (0.380 to 1.371)	.32
Ethnicity⁺	0.719 (0.382 to 1.355)	.31
Subtype^{&}		
Acral	1.208 (0.527 to 2.767)	.66
Mucosal	4.213 (1.268 to 13.999)	.02
Ocular	0.965 (0.240 to 3.879)	.96
UP	0.745 (0.276 to 2.011)	.56
Previous systemic treatment[@]	1.921 (0.943 to 3.913)	.07
Baseline LDH[^]	1.549 (0.770 to 3.115)	.22
Mutation[`]		
BRAF	1.182 (0.532 to 2.626)	.68
NRAS	0.491 (0.176 to 1.371)	.18
C-KIT	2.356 (0.533 to 10.406)	.26
M stage[%]		
M1b	1.314 (0.495 to 3.493)	.58
M1c	0.766 (0.324 to 1.814)	.55
M1d	0.956 (0.332 to 2.749)	.93
M0 (unresectable)	NA	.99
Number of organ involved[§]	1.024 (0.743 to 1.413)	.88
Response pattern		
Tumor percent change (%)[§]	1.018 (1.010 to 1.026)	<.001
Time to nadir (months)[§]	0.946 (0.871 to 1.028)	.19
PFS[§]	0.943 (0.894 to 0.993)	.03

*Logistic regression model, adjusted for target lesion size at baseline. [~]Dichotomous outcome, defined as both new lesion(s) & enlargement vs. new lesion(s) or enlargement only, with the latter as the reference group. [§]As continuous variables. [#]Female as the reference group. ⁺Non-Caucasian as the reference group. [&]Cutaneous melanoma as the reference. [@]Without previous systemic treatment as the reference group. [^]Normal baseline LDH as the reference. [`]Others as the reference group. [%]M1a as the reference group.